EMA Panel Recommends Opdivo’s European Approval for Classical Hodgkin’s Lymphoma
News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of classical Hodgkin’s lymphoma (cHL) in patients who relapsed or progressed ... Read more